Public Employees Retirement Association of Colorado cut its holdings in Axon Enterprise, Inc. (NASDAQ:AXON – Free Report) by 3.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,427 shares of the biotechnology company’s stock after selling 298 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Axon Enterprise were worth $2,185,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in AXON. 9258 Wealth Management LLC acquired a new position in shares of Axon Enterprise during the 4th quarter worth about $204,000. Beacon Pointe Advisors LLC acquired a new stake in shares of Axon Enterprise in the fourth quarter worth approximately $218,000. PNC Financial Services Group Inc. increased its position in shares of Axon Enterprise by 11.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,320 shares of the biotechnology company’s stock worth $1,116,000 after purchasing an additional 427 shares in the last quarter. Assetmark Inc. lifted its holdings in Axon Enterprise by 8.0% in the 4th quarter. Assetmark Inc. now owns 4,438 shares of the biotechnology company’s stock valued at $1,146,000 after purchasing an additional 329 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. grew its holdings in shares of Axon Enterprise by 6.9% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 8,251 shares of the biotechnology company’s stock worth $2,131,000 after buying an additional 535 shares in the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling at Axon Enterprise
In other news, Director Matthew R. Mcbrady sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $364.66, for a total transaction of $729,320.00. Following the completion of the sale, the director now owns 4,892 shares in the company, valued at approximately $1,783,916.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Julie A. Cullivan sold 900 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $353.53, for a total transaction of $318,177.00. Following the transaction, the director now owns 3,653 shares in the company, valued at approximately $1,291,445.09. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Matthew R. Mcbrady sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $364.66, for a total value of $729,320.00. Following the completion of the sale, the director now owns 4,892 shares of the company’s stock, valued at approximately $1,783,916.72. The disclosure for this sale can be found here. Insiders have sold 317,981 shares of company stock worth $115,662,734 over the last three months. Insiders own 6.10% of the company’s stock.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on AXON
Axon Enterprise Price Performance
Axon Enterprise stock opened at $393.94 on Tuesday. The stock has a market cap of $29.73 billion, a P/E ratio of 115.19, a price-to-earnings-growth ratio of 10.34 and a beta of 0.94. The company has a fifty day simple moving average of $349.75 and a 200-day simple moving average of $317.79. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. Axon Enterprise, Inc. has a 12-month low of $189.12 and a 12-month high of $397.32.
Axon Enterprise (NASDAQ:AXON – Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.18. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The business had revenue of $504.00 million during the quarter, compared to analysts’ expectations of $478.35 million. During the same period in the prior year, the firm posted $0.80 EPS. The business’s quarterly revenue was up 34.5% compared to the same quarter last year. Equities analysts expect that Axon Enterprise, Inc. will post 1.79 EPS for the current fiscal year.
Axon Enterprise Company Profile
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Further Reading
- Five stocks we like better than Axon Enterprise
- How to Use the MarketBeat Dividend Calculator
- The Average 401k Balance by Age Explained
- The How and Why of Investing in Gold Stocks
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXON – Free Report).
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.